Advertisement

Journal of Neurology

, Volume 238, Supplement 1, pp S23–S27 | Cite as

A review of current drugs for migraine

  • J. Olesen
Review Of Migraine And Its Therapy

Summary

The current treatments available for migraine are reviewed and may be classified into four basic types. (a) Identification and elimination of migraine trigger factors, which include stress, emotions, fatigue, certain foods and beverages, and certain medications such as oestrogen therapy. (b) Symptomatic treatment of individual attacks. This includes various non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin and paracetamol, and ergotamine, dihydroergotamine and phenothiazines. Morphinomimetics, which are often given for migraine, should really be avoided. (c) Prophylactic treatment which is particularly recommended for patients averaging two or more severe migraine attacks per month. Useful drugs include: ß-adrenergic receptor blockers as first choice, e.g. propranolol, timolol, nadolol and metoprolol; 5-hydroxytryptamine blockers, e.g. pizotifen and methysergide; calcium channel blockers; dihydroergotamine; and NSAIDs. (d) Non-drug treatment which is best combined with identification and elimination of trigger factors, and the use of various relaxation techniques. These four treatment types are covered in some detail, however it is clear that none of them is ideal and side-effects present a problem. Clearly, the continued research and development of novel and specific drugs for migraine is vital.

Key words

Migraine Antimigraine therapy Migraine trigger factors 

References

  1. 1.
    Andersen AR, Tfelt-Hansen P (1985) The effect of ergotamine and dihydroergotamine on cerebral blood flow in man. Cephalalgia 5 (suppl 3):50–51Google Scholar
  2. 2.
    Egger J, Carter CM, Wilson J, Turner MW, Soothill JF (1983) Is migraine food allergy? A double-blind controlled trial of oligo antigenic diet treatment. Lancet II:865–869Google Scholar
  3. 3.
    Lance JW (1982) Mechanism and management of headache, 4th edn. Butterworth, LondonGoogle Scholar
  4. 4.
    Langemark M, Olesen J (1984) Drug abuse in migraine patients. Pain 19:81–86Google Scholar
  5. 5.
    Migraine — Nimodipine European Study Group (MINES) (Olesen J Chairman) (1989) European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Headache 29:633–638Google Scholar
  6. 6.
    Migraine — Nimodipine European Study Group (MINES) (Olesen J Chairman) (1989) European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Headache 29:639–642Google Scholar
  7. 7.
    Monro J, Carini C, Brostoff J (1984) Migraine is a food-allergic disease. Lancet II:719–721Google Scholar
  8. 8.
    Olesen J (1984) Significance of trigger factors in migraine. In: Clifford Rose F (ed) Progress in migraine research 2. Pitman, London, pp 18–29Google Scholar
  9. 9.
    Olesen J (1986) The role of calicum entry blockers in the prophylaxis of migraine. Eur Neurol 25:72–79Google Scholar
  10. 10.
    Raskin NH, Appenzeller O (1980) Headache. Major problems in internal medicine 19. W B Saunders, PhiladelphiaGoogle Scholar
  11. 11.
    Swanson DW, Weddige RL, Morse RM (1973) Abuse of prescription drugs. Mayo Clin Proc 48:359–367Google Scholar
  12. 12.
    Tfelt-Hansen P (1986) Efficacy of beta-blockers in migraine a critical review. Cephalalgia 6 (suppl 5):15–24Google Scholar
  13. 13.
    Tfelt-Hansen P, Manniche PM (1984) Dose-response curve for ergotamine-induced decrease of peripheral systolic blood pressure in man. Acta Pharmacol Toxicol 55:238–241Google Scholar
  14. 14.
    Tfelt-Hansen P, Paalzow L (1985) Plasma levels and dynamic activity of intramuscular ergotamine. Clin Pharmacol Ther 37:29–35Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • J. Olesen
    • 1
  1. 1.Department of NeurologyGentofte HospitalCopenhagenDenmark

Personalised recommendations